Biocartis Group NV
XBRU:BCART
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.29
0.29
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biocartis Group NV
Income from Continuing Operations
Biocartis Group NV
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Biocartis Group NV
XBRU:BCART
|
Income from Continuing Operations
-€67.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
||
Nyxoah SA
XBRU:NYXH
|
Income from Continuing Operations
-€43.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
||
Ion Beam Applications SA
XBRU:IBAB
|
Income from Continuing Operations
-€9.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
||
Sequana Medical NV
XBRU:SEQUA
|
Income from Continuing Operations
-€27.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
Biocartis Group NV
Glance View
Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
See Also
What is Biocartis Group NV's Income from Continuing Operations?
Income from Continuing Operations
-67.9m
EUR
Based on the financial report for Jun 30, 2023, Biocartis Group NV's Income from Continuing Operations amounts to -67.9m EUR.
What is Biocartis Group NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-11%
Over the last year, the Income from Continuing Operations growth was -8%. The average annual Income from Continuing Operations growth rates for Biocartis Group NV have been -1% over the past three years , -11% over the past five years .